U.S. markets close in 2 hours 2 minutes
  • S&P 500

    3,281.02
    +34.43 (+1.06%)
     
  • Dow 30

    27,018.47
    +203.03 (+0.76%)
     
  • Nasdaq

    10,849.48
    +177.21 (+1.66%)
     
  • Russell 2000

    1,470.14
    +18.33 (+1.26%)
     
  • Crude Oil

    40.21
    -0.10 (-0.25%)
     
  • Gold

    1,867.90
    -9.00 (-0.48%)
     
  • Silver

    23.14
    -0.06 (-0.24%)
     
  • EUR/USD

    1.1631
    -0.0045 (-0.38%)
     
  • 10-Yr Bond

    0.6590
    -0.0070 (-1.05%)
     
  • GBP/USD

    1.2717
    -0.0035 (-0.27%)
     
  • USD/JPY

    105.5940
    +0.1920 (+0.18%)
     
  • BTC-USD

    10,705.72
    -54.87 (-0.51%)
     
  • CMC Crypto 200

    219.34
    +1.51 (+0.69%)
     
  • FTSE 100

    5,842.67
    +19.89 (+0.34%)
     
  • Nikkei 225

    23,204.62
    +116.80 (+0.51%)
     

Marinus Pharmaceuticals to Announce First Quarter 2020 Financial Results on Monday, May 4, 2020

RADNOR, Pa., April 23, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that it will release financial results for the first quarter ended March 31, 2020 before the market open on Monday, May 4, 2020. The Company will also host a conference call at 8:30am Eastern Time on Monday, May 4, 2020 to discuss the financial results with investors.

Monday, May 4th @ 8:30am Eastern Time

Domestic:

877-705-6003

International:   

201-493-6725

Webcast: 

http://public.viavid.com/index.php?id=139413

Conference ID: 

13702686

About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. For more information visit www.marinuspharma.com. Please follow us on Twitter: @MarinusPharma.

CONTACT: 

Sasha Damouni Ellis
Vice President, Investor Relations & Corporate Communications
Marinus Pharmaceuticals, Inc.
484-253-6792
sdamouni@marinuspharma.com